Healthcare Gainers: Bio-Path Holdings Inc (NASDAQ:BPTH), MEI Pharma Inc (NASDAQ:MEIP), OraSure Technologies, Inc. (NASDAQ:OSUR), KaloBios Pharmaceuticals Inc (NASDAQ:KBIO), Atossa Genetics Inc (NASDAQ:ATOS)

Investment analysts at Maxim Group began coverage on shares of Bio-Path Holdings (NASDAQ:BPTH) in a note issued to investors on Monday. The firm set a “buy” rating and a $5.00 price target on the stock. Bio-Path Holdings Inc (NASDAQ:BPTH) weekly performance is 5.15%. On last trading day company shares ended up $2.86. Analysts mean target price for the company is $5.00. Bio-Path Holdings Inc (NASDAQ:BPTH) distance from 50-day simple moving average is 9.73%.

MEI Pharma Inc (NASDAQ:MEIP) announced preliminary response data from the first stage of a two-stage, open-label Phase II clinical study of its investigational drug candidate Pracinostat in combination with Vidaza (azacitidine) in elderly patients with newly diagnosed acute myeloid leukemia who are unsuitable for intensive chemotherapy. MEI Pharma Inc (NASDAQ:MEIP) shares advanced 14.50% in last trading session and ended the day on $7.03. MEIP its return on assets is -46.80%. MEI Pharma Inc (NASDAQ:MEIP) quarterly performance is -31.35%.

OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled an investor conference call and simultaneous webcast for 8:30 a.m. ET (5:30 a.m. PT) on Wednesday, June 11, 2014 to provide an update on certain developments related to its OraQuick® HCV business. OraSure Technologies, Inc. (NASDAQ:OSUR) shares moved up 5.86% in last trading session and was closed at $7.23, while trading in range of $6.85-$7.26. OraSure Technologies, Inc. (NASDAQ:OSUR) year to date performance is 14.94%.

KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) will present at the Jefferies 2014 Global Healthcare Conference in New York City, NY. KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) ended the last trading day at $2.13. Company weekly volatility is calculated as 21.71% and price to cash ratio as 1.12. KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) showed a positive weekly performance of 21.71%.

Atossa Genetics Inc (NASDAQ:ATOS) said that it has hired John E. Sawyer as Senior Vice President of Global Regulatory Affairs and Quality Assurance, effective June 1. Atossa Genetics Inc (NASDAQ:ATOS) weekly performance is 15.33%. On last trading day company shares ended up $1.58. Analysts mean target price for the company is $8.75. Atossa Genetics Inc (NASDAQ:ATOS) distance from 50-day simple moving average is 12.91%.